IGC Pharma Develops MINT-AD, Proprietary AI-Powered Diagnostic Platform To Identify High Risk Cognitive Decline Years Before Symptoms Appear

- Multimodal foundation model enables personalized cognitive forecasts and expands access to Alzheimer's diagnostics -

POTOMAC, MD / ACCESS Newswire / July 10, 2025 / IGC Pharma, Inc. (NYSE:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced the development of MINT-AD, Multimodal Interpretable Transformer for Alzheimer's, the Company's proprietary AI-powered diagnostic platform designed to identify individuals at high risk of cognitive decline years before symptoms appear.

MINT-AD leverages diverse data sources including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories. The platform is being designed for integration into physician workflows to help improve early detection, care personalization and clinical trial enrolment.

IGC expects to launch a beta version of MINT-AD in Fiscal 2026 for pilot evaluation in collaboration with academic and clinical partners. Planned use cases for the platform include integration into electronic health records (EHR) or web-based tools for diagnostic support, enhancing patient stratification, including for our clinical trials, and enabling scalable cognitive assessments in resource-limited settings.